An article published in the Fall 2004 issue and updated in the Spring 2006 issue of this journal discussed a recently approved drug, Strattera, which is used for children and adults with ADHD. The article noted that one of the main attributes of the drug is the fact that it is not a stimulant medication, but rather works by blocking or slowing the reabsorption of norepinephrine, a brain chemical considered important in regulating attention, impulsivity and activity levels. The original update on Strattera reported the bolded FDA warning. The warning indicated, in part, the potential for "severe liver injury in rare cases and markedly elevated hepatic enzymes and bilirubin" ("Warning of," 2005). In spite of this warning, up to 3.4 million people have been prescribed Strattera. On June 9, 2010 the FDA warned doctors that children and adolescents who used Strattera were at increased risk of suicidal ideation. This black box warning states, "Strattera increased the risk of suicidal ideation in short-term studies in children or adolescents with attention-deficit/hyperactivity disorder (ADHD)." Anyone considering the use of Strattera in a child or adolescent must balance this risk with the clinical need. The FDA does not advise people to stop taking Strattera but to watch for signs of suicidal thinking ("ADHD medicines," 2010).